The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:1075 March 6, 2008 Number 10
NextNext

Chemotherapy in Unresectable Head and Neck Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Vermorken, J. B.
-PubMed Citation
To the Editor: Radiotherapy alone in patients with advanced head and neck cancer is not the treatment of choice, even when cisplatin, fluorouracil, and docetaxel (TPF) are given. Vermorken et al. (Oct. 25 issue)1 report that TPF improved progression-free and overall survival in patients with unresectable head and neck cancer, but their results are disappointing as compared with chemoradiotherapy2,3 or radiotherapy with cetuximab.4 In the same issue, Posner et al. also report better results in patients with advanced head and neck cancer when TPF was combined with radiotherapy.5


Edwin Bölke, M.D.
Matthias Peiper, M.D.
Stephan Gripp, M.D.
University of Düsseldorf
. . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.